How is QUICKI calculated?

QUICKI = 1 / [log₁₀(fasting insulin in mcU/mL) + log₁₀(fasting glucose in mg/dL)]. The logarithmic transformation normalizes the right-skewed distribution of insulin values. For example, with fasting insulin of 12 mcU/mL and fasting glucose of 95 mg/dL: log(12) = 1.079, log(95) = 1.978; sum = 3.057; QUICKI = 1/3.057 = 0.327.

What is a normal QUICKI value?

Based on published threshold data: QUICKI above 0.339 indicates normal insulin sensitivity; 0.302–0.339 suggests impaired insulin sensitivity consistent with metabolic syndrome, prediabetes, or early insulin resistance; below 0.302 indicates insulin resistance in the diabetes range. These thresholds were derived from NHANES data and may need adjustment for different ethnic populations.

What does QUICKI measure in PCOS?

In polycystic ovary syndrome, QUICKI quantifies the degree of insulin resistance that is present in approximately 50–70% of affected women regardless of BMI. Lower QUICKI values in PCOS correlate with higher androgen levels, worse ovulatory dysfunction, and lower response to clomiphene. Serial QUICKI monitoring tracks the metabolic response to metformin therapy, weight loss, or other insulin-sensitizing interventions over time.

Can QUICKI diagnose insulin resistance?

QUICKI can identify insulin resistance as a metabolic pattern — values below 0.302 are consistent with insulin resistance. However, it is not a diagnostic test for any specific disease. Insulin resistance is a metabolic state, not an independent diagnosis. QUICKI should be interpreted alongside clinical context, BMI, waist circumference, lipid profile, blood pressure, and glucose metabolism markers to form a complete metabolic risk assessment.

What is insulin sensitivity?

Insulin sensitivity refers to how effectively cells respond to insulin's signal to take up glucose from the bloodstream. In insulin-sensitive individuals, normal amounts of insulin efficiently lower blood glucose. In insulin-resistant individuals, the same amount of insulin produces a blunted glucose-lowering effect, requiring the pancreas to secrete more insulin to maintain normal glucose levels (compensatory hyperinsulinemia). Reduced insulin sensitivity is the underlying metabolic defect in type 2 diabetes, PCOS, metabolic syndrome, and NAFLD.

How can I improve my QUICKI score?

Strategies that improve insulin sensitivity (and thus increase QUICKI) include: weight loss of 5–7% of body weight (reduces insulin resistance by 20–40%); aerobic exercise (150+ minutes per week of moderate intensity); resistance training (increases skeletal muscle glucose uptake); dietary modifications (reduced refined carbohydrates and ultra-processed foods, higher fiber, Mediterranean-style diet); improved sleep quality (sleep deprivation acutely worsens insulin sensitivity); and medications such as metformin, GLP-1 receptor agonists, or pioglitazone in appropriate clinical settings.

Is QUICKI used in clinical practice or just research?

QUICKI is predominantly used in clinical research and metabolic studies rather than routine clinical practice. For everyday care, standard fasting glucose, HbA1c, lipid panel, and clinical assessment (BMI, waist circumference) are more commonly used. QUICKI is valuable in specialized metabolic clinics, endocrinology practices managing PCOS or metabolic syndrome, and research protocols where quantifying insulin sensitivity longitudinally is important.

Online Medical Tools — QUICKI

Printed on 9/2/2026

For informational purposes only. This is not medical advice.

Endocrinology

QUICKI

QUICKI (Quantitative Insulin Sensitivity Check Index) is a fasting surrogate marker of insulin sensitivity calculated from fasting glucose and fasting insulin. Compared with HOMA-IR, QUICKI inversely scales with insulin resistance, so lower values generally suggest greater insulin resistance.

Formula: QUICKI = 1 / (log10(Fasting Insulin) + log10(Fasting Glucose))

Fasting Glucose

mg/dL

Fasting Insulin

uIU/mL

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

Create free account Sign in

How It Works

Obtain fasting blood sample

Collect a venous blood sample after a true 8–12 hour fast (water only). Both serum insulin and plasma glucose must be drawn from the same sample. Fasting conditions are critical — even a small meal or caloric beverage will spike insulin and invalidate the result. Ensure the patient has not received any exogenous insulin within the past 24 hours.

Enter fasting insulin and glucose values

Input fasting serum insulin (in mcU/mL or μIU/mL) and fasting plasma glucose (in mg/dL). The calculator applies the QUICKI formula: 1 / [log₁₀(insulin) + log₁₀(glucose)]. The logarithmic transformation normalizes the typically right-skewed distribution of insulin values, improving the linearity of the insulin sensitivity estimate.

Interpret the QUICKI value

Results are interpreted using published threshold values: QUICKI above 0.339 indicates normal insulin sensitivity; 0.302–0.339 suggests impaired insulin sensitivity (consistent with metabolic syndrome or prediabetes); below 0.302 indicates insulin resistance in the diabetes range. Higher QUICKI values always indicate better insulin sensitivity — the scale is inverse to HOMA-IR.

Who Uses the QUICKI

Insulin Sensitivity Research Studies

Clinical researchers, metabolic investigators

QUICKI is widely used in epidemiological and intervention studies to quantify insulin sensitivity across populations. Its log-linear scaling makes it more amenable to parametric statistical analysis than HOMA-IR in some research designs, particularly when comparing treatment arms in metabolic intervention trials.

PCOS Evaluation and Monitoring

Endocrinologists, gynecologists, reproductive specialists

Insulin resistance is central to the pathophysiology of PCOS, present in 50–70% of affected women regardless of BMI. Serial QUICKI measurements can track improvement in insulin sensitivity with metformin therapy, weight loss, or lifestyle modification programs, providing objective evidence of metabolic response to treatment.

Metabolic Syndrome Screening

Primary care, cardiologists, preventive medicine

In patients with central obesity, dyslipidemia, and hypertension fulfilling metabolic syndrome criteria, QUICKI provides a quantitative measure of underlying insulin resistance beyond the qualitative ATP III or IDF diagnostic categories. Serial values over years document metabolic trajectory.

Prediabetes Risk Assessment

Diabetologists, endocrinologists

QUICKI can identify insulin resistance in individuals whose fasting glucose is still in the normal range (prediabetes is defined as fasting glucose 100–125 mg/dL). Reduced QUICKI in normoglycemic individuals predicts future progression to type 2 diabetes and helps identify candidates for intensive lifestyle intervention.

Lifestyle Intervention Response Tracking

Sports medicine, obesity medicine, lifestyle medicine

Tracking QUICKI before and after dietary changes, aerobic exercise programs, or weight loss interventions provides an objective biomarker of metabolic improvement independent of HbA1c changes. Serial QUICKI captures early improvements in insulin signaling that precede changes in glucose metrics.

Pediatric Obesity Research

Pediatric endocrinologists, pediatric researchers

QUICKI is widely used in pediatric metabolic studies, particularly in childhood obesity and adolescent metabolic syndrome research. Pediatric reference ranges differ from adult values due to pubertal insulin resistance, and QUICKI's normalized scale facilitates cross-age comparisons within longitudinal studies.

Pro Tips

Higher QUICKI always means better sensitivity — the inverse of HOMA-IR

QUICKI scales inversely to HOMA-IR: a higher number is always better. This intuitive directionality (like other 'index' measures — higher sensitivity index = better) makes QUICKI conceptually easier to communicate to patients during lifestyle counseling compared to HOMA-IR where a higher number means worse.

Both QUICKI and HOMA-IR derive from the same two fasting values

QUICKI and HOMA-IR are mathematically related — they both use only fasting insulin and fasting glucose, just arranged differently. You can calculate both from a single fasting blood draw at no extra cost. Reporting both in a metabolic evaluation provides a comprehensive picture and allows comparison with published studies using either metric.

Slightly stronger correlation with clamp in obese patients

Several validation studies have shown QUICKI correlates marginally better with the euglycemic hyperinsulinemic clamp (the gold standard for insulin sensitivity) than HOMA-IR in obese individuals, particularly at very high insulin levels. The logarithmic transformation handles extreme hyperinsulinemia better than the linear HOMA-IR formula.

True fasting is non-negotiable

An 8–12 hour fast is required for both QUICKI and HOMA-IR. Even a small caloric intake (including cream in coffee) acutely raises insulin levels, producing a falsely low QUICKI value. Verify fasting status verbally and note it in the medical record. Lipemic samples may also indicate a non-fasted state.

Population-specific cutoffs vary — South Asians need lower thresholds

The commonly cited QUICKI threshold of 0.339 was derived from predominantly White Western populations. South Asian individuals have been shown to have significant insulin resistance at QUICKI values that would appear normal by Western cutoffs. Population-appropriate reference ranges should be used when available.

QUICKI tracks intervention response over serial measurements

The real utility of QUICKI in clinical practice is longitudinal tracking — not single measurements. A patient improving their QUICKI from 0.310 to 0.330 after a 6-month lifestyle program demonstrates meaningful metabolic improvement even if neither value crosses the 0.339 threshold. Serial trends are more informative than single cross-sectional values.

Correlates with euglycemic clamp at approximately r = 0.78

Published validation data from Katz et al. (2000) demonstrated QUICKI correlation with the euglycemic hyperinsulinemic clamp at r = 0.78, slightly higher than HOMA-IR's correlation in the same dataset. Both are strong surrogate markers, making either appropriate for clinical and research use depending on which has been validated in the specific population being studied.

Cannot be used in type 1 diabetes

QUICKI is invalid in type 1 diabetes or any condition of absolute insulin deficiency because fasting insulin levels are near zero or undetectable, making the logarithm undefined or producing artifactual results. In patients on insulin therapy for T2DM, endogenous insulin cannot be separated from exogenous insulin, also invalidating the formula.

Best used as a population or research tool, not individual diagnosis

Like HOMA-IR, QUICKI is most appropriate for comparing groups, tracking populations over time, and epidemiological research. Individual values have wide confidence intervals — a single QUICKI measurement in one patient should not be used as the sole basis for a diagnosis of insulin resistance without clinical context and other metabolic markers.

Insulin assay standardization affects absolute values

Fasting insulin immunoassays are not standardized across laboratories. The same blood sample sent to different labs may yield different numerical insulin values depending on whether the assay detects proinsulin and split proinsulin. This means absolute QUICKI values are only comparable within the same laboratory method — use the same lab for serial measurements in a given patient.

Common Questions About Your Results

Fasting insulin is not part of routine metabolic panels (BMP/CMP). It must be specifically ordered as an add-on test. Many laboratories batch fasting insulin with insulin resistance panels, but the ordering physician must explicitly request it. This is one practical barrier to QUICKI use in routine clinical settings — advocacy for its inclusion in metabolic evaluations is appropriate for at-risk patients.

Type 1 diabetes involves absolute insulin deficiency, meaning endogenous fasting insulin is essentially zero. Log(0) is undefined, making the QUICKI formula mathematically invalid. Additionally, patients on exogenous insulin cannot be assessed using fasting models because the assay cannot distinguish endogenous from injected insulin. QUICKI is only valid in individuals with intact endogenous insulin secretion who are not receiving insulin therapy.

Yes. The threshold of 0.339 for normal insulin sensitivity was derived from NHANES data representing predominantly Western populations. South Asian populations tend to have insulin resistance at higher QUICKI values than Western counterparts. Pediatric populations also require age and puberty-specific reference ranges because pubertal insulin resistance transiently lowers QUICKI in normal adolescents. Always reference population-appropriate thresholds when available.

Advanced type 2 diabetes with significant beta cell failure can paradoxically produce a falsely elevated (better-appearing) QUICKI because insulin deficiency lowers fasting insulin values, which mathematically increases the QUICKI result. This is the same reason HOMA-IR can appear 'normal' in late-stage T2DM — the failing beta cell no longer produces compensatory hyperinsulinemia, so the surrogate markers underestimate the true metabolic dysfunction.

Evidence-Based Methodology

QUICKI was developed by Katz et al. (J Clin Endocrinol Metab 2000) as a simpler surrogate index of insulin sensitivity with improved statistical properties compared to HOMA-IR. Correlation with the euglycemic hyperinsulinemic clamp (reference standard) was reported at r = 0.78. The threshold of 0.339 for normal insulin sensitivity was derived from NHANES population data. QUICKI and HOMA-IR have been shown to produce equivalent results for population-level insulin resistance studies (Rabasa-Lhoret et al., 2003). Pediatric reference ranges established in multiple cohort studies including the Bogalusa Heart Study.

Clinical Content Trust

Last reviewed:: April 21, 2026
Guideline version:: General evidence framework v2026.04
Source set version:: Primary-source set v1

How to Interpret Your Result

Lower QUICKI values generally reflect lower insulin sensitivity and may indicate higher insulin resistance.

When to Use This Tool

Use QUICKI in metabolic risk assessment when fasting insulin and fasting glucose are available, especially for trend tracking over time.

Limitations

Reference cutoffs vary across populations and assays. QUICKI is not a stand-alone diagnostic test and should be interpreted in clinical context.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Changelog

April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.

Related Tools

Endocrinology

HOMA-IR

Estimate insulin resistance using fasting glucose and fasting insulin with the HOMA-IR equation.

Open Endocrinology

HbA1c Converter

Convert HbA1c to estimated average glucose (eAG): 6%=126 mg/dL, 7%=154, 8%=183, 9%=212. ADA 2026 target <7% for most adults with diabetes. Shows both mg/dL and mmol/L.

Open Cardiology

TyG Index

Calculate the Triglyceride-Glucose (TyG) Index from fasting triglycerides and fasting glucose to assess insulin resistance patterns.

Open

Frequently Asked Questions

QUICKI (Quantitative Insulin Sensitivity Check Index) is a fasting surrogate measure of whole-body insulin sensitivity derived from two simple fasting blood tests: fasting serum insulin and fasting plasma glucose. It was developed by Katz et al. in 2000 as an alternative to HOMA-IR with better mathematical properties for statistical analysis. Higher QUICKI values indicate greater insulin sensitivity; lower values indicate insulin resistance.

Both QUICKI and HOMA-IR use the same two inputs — fasting insulin and fasting glucose — but are mathematically arranged differently. HOMA-IR = (insulin × glucose) / 405; higher values indicate worse insulin resistance. QUICKI = 1 / [log(insulin) + log(glucose)]; higher values indicate better insulin sensitivity. QUICKI's logarithmic transformation provides a more normally distributed result and correlates marginally better with clamp studies in some obese populations.

Neither is definitively superior for all purposes. QUICKI was specifically designed to have better statistical properties (more normal distribution) and has slightly higher correlation with the euglycemic clamp in some validation studies. However, HOMA-IR has a much larger published literature and more population-specific reference ranges. For clinical practice, both are acceptable and most clinicians use whichever is supported by local laboratory reference ranges.

Yes, QUICKI is used in pediatric metabolic research and can be applied in clinical evaluation of children with obesity or suspected metabolic syndrome. However, reference ranges differ significantly from adults — pubertal children normally have higher insulin levels and lower QUICKI values due to physiological puberty-associated insulin resistance. Adult cutoffs should not be applied directly to adolescents; use published pediatric-specific percentile references.